Investor thesis

The category leader built the shelf. We build trust.

feel free proved the category. Easy Days brings a disclosed label and lot testing to a distribution-led 2027 plan. The $9.99 shelf price is above the estimated category leader price.

The case in numbers

Launch economics at the Q4 plan.

172,800
Q4 units

Plan case

Assumption — finalizing
$792K
Q4 sales

At $55 blended case

Assumption — finalizing
$85K
After case spend

After COGS, trade, marketing and SG&A

Assumption — finalizing
$5.91
After spend / case

On $55 blended case price

Assumption — finalizing
Current workbook · all figures pending approval

Category evidence

What feel free (Botanic Tonics) has already proven.

feel free CLASSIC reached the No. 1 spot in the Energy & Supplement category at a top-five national convenience retailer (NIQ, week ending Oct 11, 2025).

Botanic Tonics press release, Oct 2025

Distribution in over 27,000 stores and top-10 manufacturer status in the convenience energy category within three years.

Botanic Tonics press release, Oct 2024

Raised $25M from existing cap-table investors to secure kava supply chain and fund testing protocols.

BevNET, Jan 2025

Sells through an owned independent distributor network rather than large national distributors.

Botanic Tonics, Apr 2025

Facing sustained consumer-harm and dependency coverage, plus a settled class action over addiction-risk disclosure — trust and labeling are the open flank.

Fortune, Dec 2025

These are public, third-party or first-party published statements about Botanic Tonics — not Easy Days results.

The wedge

Four places we win the shelf conversation.

Full disclosure on the front of the bottle

The category's biggest liability is labeling. Easy Days states Kava + Kratom plainly, 21+, with dose and warnings up front. That is a buyer-safety argument, not just a marketing line.

Two SKUs, two legal footprints

Kava + Caffeine holds shelf where kratom is restricted. A one-SKU competitor loses the door entirely; Easy Days keeps the account.

Lab-tested every lot, published

Third-party testing per lot, made available to the buyer. Matches the compliance bar the category leader had to build after the fact.

Creator Collective instead of paid category ads

16.5% attributed commission on a 21+ creator roster — acquisition cost scales with sales instead of front-loading media spend.

Risk

What we tell investors before they ask.

Regulatory

Kratom is restricted in some states and the federal posture can move. Kava + Caffeine is the hedge — it keeps the account when Kava + Kratom can't ship.

Category reputation

Dependency and labeling coverage hits the whole category, not just the leader. Our answer is full front-label disclosure, 21+ enforcement, and published per-lot testing.

Distribution concentration

A distributor-led model means volume concentrates fast. The Q4 plan has to be spread across a named distributor target list before we commit production.

Ask

What the raise would fund.

Sizing follows the forecast, not the other way around. Once the after review unit decision lands at 172,800 units, the use of funds resolves into four buckets: first production run and packaging, distributor slotting and launch trade, POS and creator content from the marketing budget, and the sales headcount to service the route.

Raise amount not set — awaiting the full forecast